Analyst Shlomo Rosenbaum from Stifel Nicolaus maintained a Buy rating on IQVIA Holdings and increased the price target to $273.00 from $254.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shlomo Rosenbaum has given his Buy rating due to a combination of factors that highlight IQVIA Holdings’ strong positioning in the industry and its potential for growth. The company is well-situated to benefit from the overall recovery of the sector, which is expected to continue into 2026, with IQV forecasted to achieve medium-term revenue growth in the range of 6%-9%. Additionally, IQVIA’s pricing environment has normalized, signaling an increase in market activity, while its focus on expanding its Evidence-Based Precision (EBP) initiatives positions it as a leader in addressing evolving client needs.
Moreover, IQVIA’s investments in artificial intelligence (AI) technologies and its significant resources devoted toward innovation underscore its potential for improving operational efficiencies and margins over time. The firm’s strategy is further supported by regulatory developments that require more comprehensive data in clinical trials, which could create additional opportunities for IQVIA’s services. Based on these factors, alongside an improved sentiment in the industry and IQVIA’s targeted growth trajectory, the target price for its stock has been raised to $273, reflecting forward-looking valuation improvements.
According to TipRanks, Rosenbaum is a 4-star analyst with an average return of 5.9% and a 55.22% success rate. Rosenbaum covers the Financial sector, focusing on stocks such as S&P Global, Factset Research, and Moody’s.